Tsinghua University and Gates Foundation Establish Global Health Drug Discovery Institute in Beijing

According to the Bill & Melinda Gates Foundation, in an effort to build a cutting-edge platform for translational medical innovation and accelerate drug research and development for diseases affecting developing countries, Foundation Co-Chair Mr. Bill Gates met with Tsinghua University President Qiu Yong in Davos, Switzerland, on January 22. The two parties reached a consensus on jointly establishing the “Global Health Drug Discovery Institute” in Beijing and signed a memorandum of cooperation. This will mark the first time that such a research and development center has been established in China.

Tsinghua University President Qiu Yong and Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation, Jointly Witness the Formal Signing of the Memorandum of Understanding

Tsinghua University President Qiu Yong (third from left) and Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation (fourth from right), reached a consensus on the joint establishment of the Global Health Drug Discovery Institute and signed a memorandum of cooperation.

Tsinghua University Vice President Yang Bin and Trevor Mundel, President of Global Health at the Bill & Melinda Gates Foundation, Jointly Sign a Memorandum of Understanding

According to reports, the Global Health Drug Discovery Institute (Beijing) (GHDDI) aims to establish a globally operating public health and pharmaceutical innovation institution with efficient operations, comprehensive functions, and outstanding capabilities in pharmaceutical research and translation.

Upon its establishment, the Center will address the prominent disease challenges facing developing countries, including China. It will fully leverage China’s comprehensive advantages in research and development to foster international collaboration in drug discovery. The Center aims to further refine and strengthen an effective system for early-stage drug R&D, serving as a hub that connects global frontier institutions in preclinical research with downstream clinical development organizations.

As co-founding partners, the Bill & Melinda Gates Foundation will provide upfront funding for project research and development, as well as guidance on the center’s development and operations, while Tsinghua University will offer support in multiple areas, including a team of leading scientists, scientific research and operational management, initial projects, equipment, and other resources.

Meanwhile, the Global Health Drug Discovery Institute (Beijing) will enter into a strategic and technical collaboration with the California Institute for Biomedical Research. Leveraging the latter’s development experience and technological expertise, and building upon its proven track record, the Institute will pursue innovative development to enhance its capabilities and specialized expertise, thereby successfully advancing the clinical development of suitable drug candidates.

The Bill & Melinda Gates Foundation stated that China has not only achieved remarkable success in poverty alleviation but is also leveraging advances in science and technology to address the severe health challenges facing the world’s impoverished populations. The Foundation expresses strong expectations for the future potential of the Global Health Drug Discovery Institute (Beijing) to drive innovation in global pharmaceutical research and development, and hopes to collaborate with Tsinghua University to jointly advance solutions to the most urgent issues in global health and medicine.

Tsinghua University stated that it has been developing disciplines in life sciences and basic medicine since the 1980s, achieving substantial progress to date. The establishment of the Global Health Drug Discovery Institute in collaboration with the Bill & Melinda Gates Foundation represents a significant initiative by Tsinghua University to advance drug research and development. Qiu Yong, President of Tsinghua University, emphasized that while strengthening its pharmaceutical sciences discipline, Tsinghua will fully leverage the strengths of related fields—including chemistry, chemical engineering, biomedical engineering, and materials science—to comprehensively enhance the university’s scientific research capabilities in medicine and health. This effort aims to drive reform of China’s pharmaceutical R&D system and make greater contributions to public health and the pharmaceutical and healthcare sectors in China and around the world.